Bioprocess

Labroots to Host the 6th Annual Bioprocessing Virtual Event Series on April 3rd, 2024

Retrieved on: 
Thursday, March 28, 2024
University at Albany, SUNY, State university system, Analytic, Sartorius, Research, Downstream processing, Science News, BioLegend, Bioprocess, University, Drug discovery, Carbohydrate, Immortalised cell line, Biology, Quality, Labroots, Cell, Molecular biology, Eppendorf

YORBA LINDA, Calif., March 28, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific networking website and producer of educational virtual events and webinars, is thrilled to announce the 6th Annual Bioprocessing Virtual Event Series, scheduled for April 3rd, 2024. This free, day-long online event will bring together experts and enthusiasts from around the globe to delve into the latest advancements and topics in bioprocessing.

Key Points: 
  • YORBA LINDA, Calif., March 28, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific networking website and producer of educational virtual events and webinars, is thrilled to announce the 6th Annual Bioprocessing Virtual Event Series , scheduled for April 3rd, 2024.
  • This free, day-long online event will bring together experts and enthusiasts from around the globe to delve into the latest advancements and topics in bioprocessing.
  • Labroots leverages the Chati virtual event platform to offer an interactive, immersive educational digital experience.
  • Participants can use the official hashtag #LRbioprocessing to follow the conversation and connect with other members in the Bioprocessing community!

Bio-Process Systems Alliance Announces the Election of Board Members (2024/2025)

Retrieved on: 
Thursday, December 14, 2023
ILC Dover, Thermo Fisher Scientific, Business development, Sustainability, CPC, Second, Sanofi, Bioprocess, Marketing strategy, Medical device, PMP, Bio Process Systems Alliance, Doctor of Philosophy, ILC, Business, Disposable product, BPSA, Management, Align Biopharma

ARLINGTON, Va., Dec. 13, 2023 /PRNewswire/ -- The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, announced it expanded its Board of Directors to 19 members to lead the organization in 2024/2025 during its recent election.

Key Points: 
  • ARLINGTON, Va., Dec. 13, 2023 /PRNewswire/ -- The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, announced it expanded its Board of Directors to 19 members to lead the organization in 2024/2025 during its recent election.
  • "Congratulations to Kirsten, Todd and Ravi on being elected to the BPSA Executive Board and congratulations to our new and returning BPSA Board members," said Mark Petrich of Krystal Biotech, BPSA Chair.
  • "I want to thank each of our dedicated volunteer leaders who have chosen to contribute their time and expertise to the BPSA Board.
  • I look forward to working together to advance the mission of BPSA.

UK Government awards Clean Food Group funding for £1 million project to accelerate novel low-emission food production systems

Retrieved on: 
Tuesday, December 5, 2023
University, Innovation, Food, University of Bath, Biology, Bioprocess engineering, Innovate UK, Food group, Biotechnology, BBSRC, Engineering, Bioprocess, Cosmetic, UK Government Decontamination Service, Renewable energy, Pharmaceutical industry

Clean Food Group is supporting the UK's broader mission to lead the global drive for innovative bio-tech solutions to deliver a more sustainable, secure and healthy food system

Key Points: 
  • Clean Food Group is supporting the UK's broader mission to lead the global drive for innovative bio-tech solutions to deliver a more sustainable, secure and healthy food system
    LONDON, Dec. 5, 2023 /PRNewswire/ -- Pioneering UK-based bio-tech business, Clean Food Group has been awarded funding for a £1 million project to advance novel low-emission food production systems in the UK.
  • The funding will enable the rapid scale up of Clean Food Group's manufacturing capability and the development of next generation, high value microbial oils.
  • The funding from the UK Government's Novel Low-Emission Food Production Systems: Industrial Research Grant has been awarded by Innovate UK, the UK's national innovation agency, and the Biotechnology and Biological Sciences Research Council (BBSRC).
  • The funding will accelerate the Company's growth plan to deliver a market-ready technology leading to a more local, sustainable and healthy food production system.

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Retrieved on: 
Tuesday, October 17, 2023
COGS, WuXi Biologics, ESG, Fed, Contract manufacturing organization, Carbon, Contract research organization, Biopharmaceutical, G&L Musical Instruments, A-DNA, Hook effect, CHO, Bioprocess, Patient, Fine chemical

WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture.

Key Points: 
  • WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture.
  • To meet increasing demands for yield improvement, COGS reduction, and ESG consideration in the current bioprocess development, WuXi Biologics has developed WuXiUI™, offering flexible and cost-effective bioprocessing solutions for global clients.
  • WuXiUI™ reduces drug substance manufacturing COGS by an estimated 60-80% compared to traditional fed-batch processes in single-use bioreactors, enhancing the competitiveness of commercial products.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are pleased to launch the WuXiUI™ platform to provide diverse bioprocessing solutions for global clients that enhance productivity and product quality, and tremendously reduce product COGs.

Nirrin appoints Greg Crescenzi as Chief Executive Officer

Retrieved on: 
Tuesday, October 10, 2023
Hardware, Semiconductor, Data Management, Manufacturing, Technology, Nanotechnology, General Health, Other Technology, Other Manufacturing, Science, Software, Other Science, Health, Engineering, Research, Multimedia, Cell, Business Leaders for Michigan, STEP, MIT, Improper integral, Bioprocess, Merck Millipore, Management

Nirrin Technologies , a company developing analytical systems to transform analysis for bioprocessing operations, announced that Greg Crescenzi has joined the company as its Chief Executive Officer.

Key Points: 
  • Nirrin Technologies , a company developing analytical systems to transform analysis for bioprocessing operations, announced that Greg Crescenzi has joined the company as its Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20231010407829/en/
    “Greg brings 30 years of strategic leadership in life science and biomanufacturing, and a long-standing history in commercializing industry-first tools and technologies,” said Matt Gunnison, CEO of Gamma Biosciences, a Nirrin strategic investor.
  • While at Cytiva he also served as Business Leader for Cell Culture Services, Xcellerex and Microcarriers, launching flagship products and quadrupling revenue.
  • I’m excited to see how our new STEP program partners utilize the HPTLS platform to speed time to answer in their own bioprocesses,” said Greg Crescenzi, CEO of Nirrin.

Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

Retrieved on: 
Monday, October 2, 2023
Improper integral, ASIA, Genomics, Lonza, Danaher, MBA, CCO, Business administration, Repligen, Repligen Corporation Award in Chemistry of Biological Processes, Growth, Bioprocess, Emlyon Business School, Fine chemical, Management, Basel, Chemistry

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately.

Key Points: 
  • WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately.
  • Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing.
  • Mr. Loeillot joins Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets.
  • Hunt, Chief Executive Officer at Repligen, said, “We are delighted to welcome Olivier to our team at Repligen.

ChromaTan™ Appoints Dr. Rajiv Datar as New CEO

Retrieved on: 
Tuesday, September 19, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Food and Bioprocess Technology, Drug development, Massachusetts Institute of Technology, KTH Royal Institute of Technology, Exhibition, Bioprocess, Conference, Biochemical engineering, Fine chemical

ChromaTanTM announced today that Dr. Rajiv Datar has been appointed the new President & CEO of the company.

Key Points: 
  • ChromaTanTM announced today that Dr. Rajiv Datar has been appointed the new President & CEO of the company.
  • Recently, Dr. Datar was the Co-Founder & CEO of a biotech startup that developed an early-stage asset, which was acquired by a Global Top-5 Biopharma Company.
  • “It was immediately clear that Dr. Datar was the right fit,” said Steve Carpenter, Chair of the Board of Directors’ compensation committee.
  • “The board of ChromaTan is so pleased to have Dr. Datar join the company in this role.

Announcing Benchling Bioprocess, the End-to-End Solution for Modern, High-throughput Process Development

Retrieved on: 
Tuesday, September 19, 2023
Cloud, Sequence, Drug development, PD, Data collection, Research, RNA, Pluto, JMP, SAN, Bioprocess, API, Create, Safety, Data science, Software, Fine chemical, Medical device

SAN FRANCISCO, Sept. 19, 2023 /PRNewswire/ -- Benchling announced Benchling Bioprocess, a cloud-native, end-to-end solution for modern, high-throughput process development today at Benchtalk, the company's annual customer event. More than one hundred customers are already using Benchling products today for process development. Now, with Benchling Bioprocess, development teams will have access to new functionality including a visual recipe designer, guided batch execution, and pre-built instrument integrations, all with a modern, easy-to-use interface that promotes fast and accurate data collection. The impact for customers is accelerated process development cycles by harnessing data at scale, a simplified tech transfer with structured, traceable process design, and better data science via an open data platform.

Key Points: 
  • More than one hundred customers are already using Benchling products today for process development.
  • Process development teams face increased market pressure to move promising discoveries into manufacturable products.
  • Benchling Bioprocess delivers a unified solution that process development teams need in order to thrive in the modern era of biopharmaceutical development.
  • Bioprocess will be part of the Benchling R&D Cloud, providing customers with purpose-built solutions for both research and process development all on a unified platform.

Precision Fermentation Fuels Growth in Ophthalmic Viscoelastic Devices Market: Opportunities and Key Segments - ResearchAndMarkets.com

Retrieved on: 
Friday, September 15, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Pressure, ASP, Strategic planning, COVID-19, Eye, OVD, Bacteria, Aqueous humour, Hurtigruten AS, Investment, Bioprocess, SWOT analysis, Growth, Meat, Melt, Forecast, Impossible Foods, Retail, Marketing, Telecommunications

This report provides a comprehensive analysis of the Ophthalmic Viscoelastic Devices (OVD) market, highlighting key trends, market dynamics, and valuable insights for stakeholders.

Key Points: 
  • This report provides a comprehensive analysis of the Ophthalmic Viscoelastic Devices (OVD) market, highlighting key trends, market dynamics, and valuable insights for stakeholders.
  • Ophthalmic viscoelastic devices, commonly known as OVDs, play a crucial role in intraocular surgeries.
  • Regional Insights: The Asia Pacific region is expected to register the highest CAGR in the precision fermentation ingredients market.
  • Revenue Growth: Drive revenues by identifying market categories and segments offering maximum opportunities for consolidations, investments, and strategic partnerships.

Global Precision Fermentation Ingredients Market: Explosive Growth with 44.0% CAGR, Reaching $36.3 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 15, 2023
Retail, Pharmaceutical, Health, Food, Beverage, ADM, Enzyme, Hemoprotein, Fermentation, Research, Carbon, Fungus, USD, Investment, Bioprocess, Egg white, Growth, Ingredient, Region, Meat, Dietary supplement, Fine chemical, Food preservation, Bacteria

The global precision fermentation ingredients market is set for remarkable growth, with an estimated value of USD 2.8 billion in 2023 and a projected increase to USD 36.3 billion by 2030.

Key Points: 
  • The global precision fermentation ingredients market is set for remarkable growth, with an estimated value of USD 2.8 billion in 2023 and a projected increase to USD 36.3 billion by 2030.
  • Precision fermentation, which involves lab-grown ingredients, demands substantial investments in research and development to expedite product commercialization.
  • Rising concerns for animal welfare, environmental sustainability, and the demand for alternative proteins have also fueled the market's momentum for precision fermentation ingredients.
  • Asia Pacific Growth: The Asia Pacific region is expected to exhibit the highest CAGR in the precision fermentation ingredients market.